Cardiovascular risks in patients with psoriasis : A systematic review
DOI:
https://doi.org/10.33448/rsd-v13i9.46682Keywords:
Psoriasis; Risk factors; Cardiovascular risk.Abstract
Psoriasis is a chronic inflammatory disease characterized by immune mediated skin inflammation and hyperproliferation of keratinocytes, resulting in erythematous plaques or papules covered with silvery scales, primarily affecting extensor surfaces, nails, scalp, and trunk, often accompanied by itching and irritation during active phases. It exhibits clinical variability and can manifest in various forms, including plaque, nail, guttate, inverse, pustular, erythrodermic, and psoriatic. This condition has a genetic predisposition, and when combined with environmental and behavioral factors, plays a significant role in disease progression. The prevalence of cardiovascular risk factors and metabolic disorders has been found to be high in psoriasis patients, possibly due to the inflammatory nature common to both conditions. Current studies suggest that the inflammatory nature of psoriasis may be linked to a predisposition to other diseases with altered inflammatory status, particularly cardiovascular diseases. This study aims to provide a synthesis of current and relevant information regarding the association between psoriasis and cardiovascular risk factors. Information was obtained through a systematic review, of a descriptive and exploratory nature, using the PRISMA method, searching for articles in the PubMed and BVS databases with the keywords "Psoriasis," "Cardiovascular disease," and "Risk factors." The review included articles from Controlled Clinical Trials published between 2018 and 2023, demonstrating the connection between psoriasis and cardiovascular damage, as well as the need for further in-depth studies on the subject, as well as methods for screening, prevention, and treatment of cardiovascular risk factors in psoriasis patients.
References
Alfaddagh, A S S et al.(2020). Inflammation and cardiovascular disease: from mechanisms to therapeutics. American Journal Of Preventive Cardiology, 2020; 4, 100-130.
Ayala, F. .(2009). Clinical Aspects and Comorbidities of Psoriasis. The Journal Of Rheumatology Supplement, [S.L.], 83, 19-20, 1 ago. 2009. The Journal of Rheumatology. http://dx.doi.org/10.3899/jrheum.090214.
Calvayrac, O et al. .(2011). CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-κB. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31(11), 2733-2741. ISSN 1524-4636.
Candido, C C P. .(2012). Avaliação da eficácia de um grupo psicoeducativo sobre ansiedade, depressão e qualidade de vida de pacientes com psoríase. FFCLRP - Departamento de Psicologia. Ribeirão Preto – SP, 2012.
Conforti, C et al. .(2020). Moderate-to-severe plaque psoriasis, described by PASI ≥10%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk. Dermatologic therapy. 2020; 33(6). ISSN 1529-8019.
Duarte, G V et al. .(2010). Psoríase e obesidade: revisão de literatura e recomendações no manejo. Anais Brasileiros de Dermatologia, 2010; 85(3), 355-360.
Elnabawi, A Y et al. .(2019). Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovascular Research, 2019; 115(4): 721-728.
Gomes, I. S. & Caminha, I. O. (2014). Guia para estudos de revisão sistemática. Movimento. 20(1), 395-411.
Griffiths, C; & Barker, J N. .(2010). Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. (8. ed.). Massachusetts: Wiley-Blackwell; 2010. p. 20.1-20.60.
Henseler, T. .(1998). Genetics of psoriasis. Arch Dermatol Res. 1998; 290(9), 463-76.
Hu, M Y, Yang G, & Zheng J. .(2020). The association of psoriasis and hypertension: focusing on anti‐inflammatory therapies and immunological mechanisms. Clin Exp Dermatol. 2020; 45(7), 836-840.
Jlaravuthisan, M M et al. .(2007). Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1),1-27.
Kerkhof P C; Schalkwijk, J. Psoriasis. In: Bolognia J L, Jorizzo J L, &Rapini R P, eds. .(2008). Dermatology. (2. ed.). New York: Mosby; 2008. p. 115-34.
Klockner, G M D, et al. .(2022). Relation between psoriasis and cardiovascular diseases: An integrative review. Rev. Méd. Paraná, Curitiba, 2022; 80(1), e1695.
Libby, P; Ridker, P M, & Maseri, A. .(2002). Inflammation and atherosclerosis. Circulation. 2002; 105(9):1135-1143. ISSN 1524-4539.
Lopes, VO; Martins BA. Resumo sobre psoríase (completo)| LIGAS. NUDEMES UFC - Núcleo de Desenvolvimento Médico de Sobral. 2020.
Palma, S, et al. .(2020). Consenso brasileiro de psoríase 2020: Algoritmo de tratamento da Sociedade Brasileira de Dermatologia. (3. ed. atual.). Sociedade Brasileira de Dermatologia, 2020. 138 p. ISBN: 978-65-992880-1-2.
Porro, A M, et al. .(2012). Consenso brasileiro de psoríase 2012: guias de avaliação e tratamento. (2. Ed.). Sociedade Brasileira de Dermatologia. 2012.
Rodrigues, A P; & Teixeira, R M. .(2009). Desvendando a psoríase. Revista Brasileira de Análises Clínicas (RBAC), vol. 41(4), 303-309, 2009.
Sajja, A, et al. .(2020). Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. JCI insight, 2020; 5(22).
Sampaio, S A P; & Rivitti, E A. .(2018). Dermatologia.( 4. ed). 2018.
Sileno, S, et al. .(2021). microRNAs involved in psoriasis and cardiovascular diseases. Vasc Biol. 2021; 3(1), R49-R68.
Silveira, M E B. Neto G P, Ferreira F R. .(2017). Perfil epidemiológico e qualidade de vida na psoríase. Rev Soc Bras Clin Med. 2017.
Singh, P; & Silverberg J I. .(2021). Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis. Archives of dermatological research. 2021; 313(3), 163-171. ISSN 1432-069X.
Teklu, M; Parel, P M; Mehta, N N. .(2021). Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health. Psoriasis (Auckl) 2021;11, 99.
Vasconcellos, C, et al. .(1995). Erythroderma: analysis of 247 cases. Rev Saúde Pública. 1995; 29, 177-82.
Vena, G A; Vestita, M; & Cassano, N. .(2010). Psoriasis and cardiovascular disease. Dermatol Ther. 2010; 23(2), 144-51.
Wollina U et al. .(2010). Psoriatic arthritis. Dermatol Ther. 2010;23(2), 123-36.
Yan, D, et al. (2021). New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. The Journal of Investigative Dermatology. 2021; 141(9), 2112-2122. ISSN 1523-1747.
Zwain, A; Aldiwani,M; & Taqi, H. .(2022). The Association Between Psoriasis and Cardiovascular Diseases. Eur Cardiol. 2021; 16:e19. Rev. Méd. Paraná, Curitiba, 2022; 80(1), e16953.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alexandra Brugnera Nunes de Mattos; Mayara Gazolla Ribeiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
